Cargando…
GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated
BACKGROUND: Incretin therapies appear to provide cardioprotection and improve cardiovascular outcomes in patients with diabetes, but the mechanism of this effect remains elusive. We have previously shown that glucagon-like peptide (GLP)-1 is a coronary vasodilator and we sought to investigate if thi...
Autores principales: | Aetesam-ur-Rahman, Muhammad, Giblett, Joel P., Khialani, Bharat, Kyranis, Stephen, Clarke, Sophie J., Zhao, Tian X., Braganza, Denise M., Clarke, Sarah C., West, Nick E. J., Bennett, Martin R., Hoole, Stephen P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088691/ https://www.ncbi.nlm.nih.gov/pubmed/33932990 http://dx.doi.org/10.1186/s12872-021-02030-5 |
Ejemplares similares
-
Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios
por: Aetesam‐ur‐Rahman, Muhammad, et al.
Publicado: (2022) -
Adenosine‐Induced Coronary Steal Is Observed in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction
por: Aetesam‐ur‐Rahman, Muhammad, et al.
Publicado: (2021) -
GLP‐1 Is a Coronary Artery Vasodilator in Humans
por: Clarke, Sophie J., et al.
Publicado: (2018) -
Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion
por: Giblett, Joel P., et al.
Publicado: (2019) -
Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016)